This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
VIVO Cannabis Past Earnings Performance
Past criteria checks 0/6
Key information
-28.1%
Earnings growth rate
-5.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 25.4% |
| Return on equity | -127.5% |
| Net Margin | -190.5% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow VIVO Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 25 | -48 | 16 | 0 |
| 30 Sep 22 | 25 | -108 | 16 | 0 |
| 30 Jun 22 | 25 | -105 | 16 | 0 |
| 31 Mar 22 | 26 | -70 | 16 | 0 |
| 31 Dec 21 | 25 | -70 | 16 | 0 |
| 30 Sep 21 | 24 | -45 | 18 | 0 |
| 30 Jun 21 | 26 | -49 | 18 | 0 |
| 31 Mar 21 | 30 | -48 | 19 | 0 |
| 31 Dec 20 | 33 | -56 | 21 | 0 |
| 30 Sep 20 | 35 | -33 | 20 | 0 |
| 30 Jun 20 | 33 | -38 | 23 | 0 |
| 31 Mar 20 | 28 | -47 | 24 | 0 |
| 31 Dec 19 | 25 | -31 | 24 | 0 |
| 30 Sep 19 | 22 | -27 | 29 | 0 |
| 30 Jun 19 | 18 | -26 | 28 | 0 |
| 31 Mar 19 | 14 | -13 | 26 | 0 |
| 31 Dec 18 | 10 | -25 | 27 | 0 |
| 30 Sep 18 | 4 | -28 | 24 | 0 |
| 30 Jun 18 | 2 | -23 | 21 | 0 |
| 31 Mar 18 | 1 | -33 | 20 | 0 |
| 31 Dec 17 | 1 | -29 | 15 | 0 |
| 30 Sep 17 | 1 | -21 | 10 | 0 |
| 30 Jun 17 | 1 | -19 | 8 | 0 |
| 31 Mar 17 | 1 | -9 | 6 | 0 |
| 31 Dec 16 | 1 | -6 | 5 | 0 |
| 30 Sep 16 | 0 | -4 | 3 | 0 |
Quality Earnings: 23Q is currently unprofitable.
Growing Profit Margin: 23Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 23Q is unprofitable, and losses have increased over the past 5 years at a rate of 28.1% per year.
Accelerating Growth: Unable to compare 23Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 23Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.4%).
Return on Equity
High ROE: 23Q has a negative Return on Equity (-127.5%), as it is currently unprofitable.